BEDFORD, Mass., Oct. 25, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products, announced today that the U.S. Food and Drug Administration (FDA) has cleared two Hologic magnetic resonance imaging (MRI) products: the Sentinelle 2-channel Endo Coil and Sentinelle's 16 channel Breast Coil for several Siemens platforms.
The Sentinelle MRI Endo Coil array for pelvic imaging provides a new solution for imaging and analysis of the pelvic region. The Endo Coil employs Hologic's innovative technology designed to provide high signal-to-noise imaging to help visualize and localize cancers in the pelvic region, and especially prostate cancer. Siemens and Toshiba are completing final release processes to enable product shipments in 2012.
Hologic's new 16 channel Sentinelle Breast Coil builds on the Company's strength in breast MRI interventional and analysis solutions for managing breast cancer. The new Breast Coil array is designed to provide excellent signal-to-noise ratio as well as optimal access for breast biopsies. The 16 channel array is pending validation by Siemens and will initially be available on the Siemens TIM (Total Imaging Matrix) platforms, followed by validation on the Siemens Aera and Skyra MRI platforms.
"We are excited about the possibilities these new products bring healthcare professionals for finding and treating breast and prostate cancer at the earliest stage possible," says Peter Soltani, Ph.D., Senior Vice President and General Manager of Hologic's Breast Health Division. "For the past decade, Hologic has worked diligently to help healthcare professionals diagnose and treat breast cancer at its earliest stages. Our newest 16 channel Sentinelle MRI Breast Coil array is yet another innovative tool added to that arsenal. In addition, we are very pleased with the FDA clearance of our new Sentinelle Endo Coil to address another debilitating disease state: prostate cancer."
About Hologic MRI Solutions
Hologic offers imaging, interventional and analysis solutions for breast MRI. Unlike competitive breast coils, Hologic's Variable Coil Geometry feature allows for the diagnostic coils and biopsy grid positioning to conform to each patient. This innovation can improve image quality, decrease set-up time, increase patient accommodation and improve access to lesions for biopsy. When combined with the Hologic ATEC minimally-invasive breast biopsy device for MRI and Hologic Aegis software for image analysis and interventional planning, the Company provides a unique suite of products.
The Company's MRI Endo Coil array for pelvic imaging provides a new solution for imaging and analysis of the pelvic region including the prostate, cervix, colon and the surrounding tissues in the pelvis. Complementing the Endo Coil array, MRI solutions offer a prostate plug in for analysis of prostate MR images to the Aegis software platform.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.
Hologic, Aegis, ATEC, Sentinelle, Variable Coil Geometry and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners.
Forward Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the Hologic MRI products. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Breast Health Marketing
SOURCE Hologic, Inc.